Biased activation of β2-AR/Gi/GRK2 signal pathway attenuated β1-AR sustained activation induced by β1-adrenergic

Hao Chen1, Ning Cao1,2, Li Wang3

  • 1Department of Physiology & Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, PR China.

Cell Death Discovery
|November 9, 2021
PubMed

Insights

Heart failure involves β1-adrenoceptor (β1-AR) autoantibodies (β1-AA) causing sustained receptor activation by blocking endocytosis. Targeting the β2-AR/Gi/GRK2 pathway promotes β1-AR endocytosis, stopping signaling and reducing heart damage.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Immunology

Background:

  • Heart failure, a terminal cardiac disease stage, is linked to β1-adrenoceptor (β1-AR) autoantibodies (β1-AA).
  • β1-AA continuously activates β1-AR, inducing cardiomyocyte apoptosis and heart dysfunction.
  • The precise mechanism of persistent β1-AR activation by β1-AA and the role of β2-adrenoceptor (β2-AR) remain unclear.

Purpose of the Study:

  • To elucidate the mechanism of sustained β1-AR activation by β1-AA.
  • To investigate the involvement of the β2-AR/Gi-signaling pathway in this process.
  • To explore therapeutic strategies targeting this pathway to mitigate heart damage.

Main Methods:

  • Neonatal rat cardiomyocyte assays (beating frequency, cAMP, Ca2+ levels) to assess β1-AA activation.
  • Total internal reflection fluorescence microscopy to visualize β1-AR endocytosis.
  • Surface plasmon resonance to study β2-AR and β1-AA interactions.
  • In vitro and in vivo experiments using ICI118551 to modulate β2-AR/Gi function.

Main Results:

  • Monoclonal β1-AA continuously activated β1-AR by inhibiting its endocytosis, which was reversible by β-arrestin1/2 overexpression.
  • β2-AR promotes β1-AR endocytosis, but β1-AA interferes with β2-AR binding to β1-AR.
  • ICI118551 biasedly activated the β2-AR/Gi/GRK2 pathway, arresting limited endocytosis and sustaining β1-AR activation by β1-AA.
  • In vivo, ICI118551 treatment reduced myocardial damage and left ventricular dysfunction in β1-AA-positive mice.

Conclusions:

  • β1-AA causes sustained β1-AR activation by inhibiting receptor endocytosis.
  • Biased activation of the β2-AR/Gi/GRK2 pathway can promote β1-AA-restricted β1-AR endocytosis.
  • This targeted endocytosis can terminate signaling and alleviate cardiac damage, offering a potential therapeutic approach.

Related Concept Videos

GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.7K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.1K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
2.7K
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
907
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
13.3K
Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
3.7K